Difference between revisions of "Team:SDU-Denmark/Tour33"

 
(19 intermediate revisions by 3 users not shown)
Line 6: Line 6:
 
<h1 align="center"> Business </h1>
 
<h1 align="center"> Business </h1>
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:195px; height:210px;">
+
<div class="thumbinner" style="width:185px; height:200px;">
<a href="https://static.igem.org/mediawiki/2015/d/dd/SDU2015_Business_Model_Canvas.png" width="190px;">
+
<a href="https://static.igem.org/mediawiki/2015/d/dd/SDU2015_Business_Model_Canvas.png" width="180px;">
<img target="_blank" src="https://static.igem.org/mediawiki/2015/a/a0/SDU2015_Business_Model_Canvas_thumbnail.png" width="190px;"></a>
+
<img target="_blank" src="https://static.igem.org/mediawiki/2015/a/a0/SDU2015_Business_Model_Canvas_thumbnail.png" width="180px;"></a>
 
<div class="thumbcaption">Figure 1: Business model canvas for PAST. </div>
 
<div class="thumbcaption">Figure 1: Business model canvas for PAST. </div>
 
</div>
 
</div>
Line 14: Line 14:
  
 
<p>
 
<p>
<span class="intro">We in PAST</span> believe that our product is a valuable addition to the toolbox of researchers and educators. But believing is not knowing, therefore an investigation is conducted to conclude whether this presumption is wrong. This evaluation consists of a business canvas, a market analysis base on iGEM teams from 2014 and a cost analysis. Allowing us to assess if profit margins are large enough to verify our assumption.
+
<span class="intro">We in PAST</span> believe that our product is a valuable addition to the toolbox of researchers and educators. But believing is not knowing, and therefore an investigation was conducted to conclude whether this presumption is wrong. This evaluation consists of a business canvas, a market analysis based on iGEM teams from 2014 and a cost analysis, allowing us to assess if profit margins are large enough to verify our assumption.
 
</p>
 
</p>
<p>
 
  
</p>
 
  
 
<p>
 
<p>
<span class="intro">The market</span> has to been evaluated to determine how many batches PAST should be able to produce per year. The analysis is based on the competitors of iGEM 2014. These teams are at the forefront of synthetic biology and therefore it is assumed, that they represent the future of the field. Every team who has succeeded in making their wiki has been considered. The results can be viewed in pdf (<a target="_blank" href="https://static.igem.org/mediawiki/2015/8/81/SDU2015_Market_analysis_the_iGEM_2014.pdf">Market analysis iGEM 2014</a>).  
+
<span class="intro">A market analysis</span> was conducted to determine how many batches PAST should be able to produce per year. The analysis is based on the competitors of iGEM 2014. These teams are at the forefront of synthetic biology and therefore it is assumed, that they represent the future of the field. Every team who has succeeded in making their wiki has been considered. The results can be viewed in the following pdf (<a target="_blank" href="https://static.igem.org/mediawiki/2015/8/81/SDU2015_Market_analysis_the_iGEM_2014.pdf">Market analysis iGEM 2014</a>).  
  
 
</p>
 
</p>
Line 32: Line 30:
  
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:255px; height:260px;">
+
<div class="thumbinner" style="width:205px; height:230px;">
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/b/bc/SDU2015_Business_TeamDistrubution_kopi.png">
+
<a class="popupImg alignRight" style="width:200px" target="_blank" href="https://static.igem.org/mediawiki/2015/b/bc/SDU2015_Business_TeamDistrubution_kopi.png">
   <img src="https://static.igem.org/mediawiki/2015/b/bc/SDU2015_Business_TeamDistrubution_kopi.png" style="width:250px"/></a>
+
   <img src="https://static.igem.org/mediawiki/2015/b/bc/SDU2015_Business_TeamDistrubution_kopi.png" style="width:200px"/></a>
     <div class="thumbcaption"><i> Figure 1:</i></div>
+
     <div class="thumbcaption">Figure 2: Chart of the global distribution of teams</div>
 
</div>
 
</div>
 
</div>
 
</div>
  
 
<p>
 
<p>
<span class="intro">The market is presumed</span> to be worldwide. The distribution of teams, which can be viewed in  figure 1, shows an even distribution in all but one region. This underrepresentation by Latin America can be caused by several factors, but for now it is considered a future market, and no correlations will be made.
+
<span class="intro">The market is presumed</span> to be worldwide. The distribution of teams, which can be viewed in  figure 2, shows an even distribution in all but one region. This underrepresentation by Latin America can be caused by several factors, but for now it is considered a future market, and no correlations will be made.
  
 
<br>
 
<br>
Line 50: Line 48:
 
<br>
 
<br>
 
<br>
 
<br>
 +
<br>
 +
 
</p>
 
</p>
  
Line 62: Line 62:
  
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:255px; height:260px;">
+
<div class="thumbinner" style="width:205px; height:230px;">
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/3/30/SDU2015_Business_TeamsUsingAntibodies_kopi.png">
+
<a class="popupImg alignRight" style="width:200px" target="_blank" href="https://static.igem.org/mediawiki/2015/3/30/SDU2015_Business_TeamsUsingAntibodies_kopi.png">
  <img src="https://static.igem.org/mediawiki/2015/3/30/SDU2015_Business_TeamsUsingAntibodies_kopi.png" style="width:250px"/></a>
+
  <img src="https://static.igem.org/mediawiki/2015/3/30/SDU2015_Business_TeamsUsingAntibodies_kopi.png" style="width:200px"/></a>
  <div class="thumbcaption"><i> Figure 2:</i></div>
+
  <div class="thumbcaption">Figure 3: Chart of teams using antibodies distributed in regions</div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 71: Line 71:
  
 
<p>
 
<p>
<span class="intro">It has also</span> been investigated, how many teams used antibodies in regards to the regions, the result is represented in figure 2. Though Europe only represents 28% of the total teams, these team teams use antibodies significantly more at 55% out of all teams. Whereas North American teams used antibodies half as much.
+
<span class="intro">We have investigated</span> how many teams according to regions that have used antibodies in their project. The results are depicted in figure 3. Though Europe only represents 28 % of the total teams, these teams use 55% of the totale usage of antibodies, whereas North American teams used antibodies half as much as they are represented.
Several reasons can be responsible for this under- and overrepresentation. If it is assumed, that all teams producing proteins could potentially use antibodies, it is a possibility that projects on this subject is more common in Europe than in North America,this will be investigated next.
+
Several reasons can be responsible for this under- and overrepresentation. If it is assumed, that all teams producing proteins could potentially use antibodies, it is a possibility that projects on this subject is more common in Europe than in North America. This will be investigated next.
  
  
Line 91: Line 91:
  
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:255px; height:250px;">
+
<div class="thumbinner" style="width:205px; height:230px;">
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/3/34/SDU2015_Business_TeamsProducingProteins_kopi.png">
+
<a class="popupImg alignRight" style="width:200px" target="_blank" href="https://static.igem.org/mediawiki/2015/3/34/SDU2015_Business_TeamsProducingProteins_kopi.png">
<img src="https://static.igem.org/mediawiki/2015/3/34/SDU2015_Business_TeamsProducingProteins_kopi.png" style="width:250px"/></a>
+
<img src="https://static.igem.org/mediawiki/2015/3/34/SDU2015_Business_TeamsProducingProteins_kopi.png" style="width:200px"/></a>
  <div class="thumbcaption"><i> Figure 3:</i></div>
+
  <div class="thumbcaption">Figure 4: Chart of teams producing protein in regards to regions</div>
 
</div>
 
</div>
 
</div>
 
</div>
  
 
<p>
 
<p>
<span class="intro">Figure 3 shows</span> that the teams producing proteins follow the general distribution globally, therefore it can be concluded that subject is not the issue in antibody usage. It has not been possible to determine if resources is the cause of the bias, but it does not seem unreasonable. If this is the case, teams will benefit from PAST’s product globally.
+
<span class="intro">Figure 4 shows</span> that the teams producing proteins follow the general distribution globally, therefore there is no correlation between protein production and the uneven distribution of antibody usage. It has not been possible to determine if resources is the cause of the bias, but this does not seem unreasonable. If that is the case, teams will benefit from PAST’s product globally.
  
 
</p>
 
</p>
  
 
<p>
 
<p>
<span class="intro">Still investigating</span> whether resources play a role in choice of antibody usage. Teams producing proteins and teams using antibodies has been compared in figure 4. This shows that only a few actually use antibodies. This could be due to teams not reaching a point, where assays using antibodies is needed, rather than a lack of resources. It has been decided to ignore this as a reason, since it must be assumed, that research projects generally have more time to evolve. Therefore it has been decided to base the estimate of production size on the protein production rather than antibody usage.
+
<span class="intro">Teams producing proteins</span> and teams using antibodies has been compared in figure 4. This shows that only a few actually use antibodies. This could be due to teams not reaching a point, where assays using antibodies are necessary, rather than a lack of resources. However, it has been decided to ignore this as a reason, since it must be assumed, that research projects generally have more time to evolve. Therefore it has been decided to base the estimate of production size on the protein production rather than antibody usage.
 
</p>
 
</p>
  
  
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:255px; height:260px;">
+
<div class="thumbinner" style="width:205px; height:260px;">
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/9/99/SDU2015_Business_ProteinsvsAntibodiyUsage_kopi.png" title="">
+
<a class="popupImg alignRight" style="width:200px" target="_blank" href="https://static.igem.org/mediawiki/2015/9/99/SDU2015_Business_ProteinsvsAntibodiyUsage_kopi.png" title="">
   <img src="https://static.igem.org/mediawiki/2015/9/99/SDU2015_Business_ProteinsvsAntibodiyUsage_kopi.png" style="width:250px"/>
+
   <img src="https://static.igem.org/mediawiki/2015/9/99/SDU2015_Business_ProteinsvsAntibodiyUsage_kopi.png" style="width:200px"/>
 
</a>
 
</a>
  <div class="thumbcaption"><i> Figure 4:</i></div>
+
  <div class="thumbcaption">Figure 5:comparison of protein production and antibody usage</div>
 
</div>
 
</div>
 
</div>
 
</div>
  
 
<p>
 
<p>
<span class="intro">Now the estimate</span> can be made. In all 123 teams where involved in such projects producing proteins, and on average the teams used two types of antibodies per project. Therefore a production of approximately 250 varieties of peptide aptamers is presumed appropriate. Though this estimates the number of batches per year, each project will only buy a small amount of the production. Therefore it should be evaluated if, it is reasonable to assume that the rest of the production can be sold as well. To reach a conservative estimate the European market has been evaluated, as this is the region where most antibodies where used. 63 universities were represented at iGEM 2014 out of approximately 4000 academic institutions in Eur<span class="sourceReference">ope</span>.  
+
<span class="intro">Using the assumption</span> an estimate can be made. A total of 123 teams where involved in projects producing proteins, and on average the teams used two types of antibodies per project. Therefore a production of approximately 250 varieties of peptide aptamers is presumed appropriate. Though this estimates the number of batches per year, each project will only buy a small amount of the production. Therefore it should be evaluated if, it is reasonable to assume that the rest of the production can be sold as well. To reach a conservative estimate the European market has been evaluated, as this is the region where most antibodies where used. 63 universities were represented at iGEM 2014 out of approximately 4000 academic institutions in Eur<span class="sourceReference">ope</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 126: Line 126:
 
</span>   
 
</span>   
  
Taking these numbers into account iGEM 2014 represents 1.6% of the market. Assuming only one research project per university is using antibodies, which is unlikely. This evaluation reinforces the assumption, that the remaining product can be sold. In some instances this will not be the case, due to the specialized nature of production or property rights therefore it is estimated that 30% of the production will be lost.
+
Taking these numbers into consideration, iGEM 2014 represents 1.6 % of the market. Assuming only one research project per university is using antibodies, which is unlikely, this evaluation reinforces the assumption, that the remaining product can be sold. In some instances this will not be the case, due to the specialized nature of production or property rights. Therefore it is estimated that 30 % of the production will be lost.
  
 
</p>
 
</p>
Line 134: Line 134:
  
 
<p>
 
<p>
<span class="intro">The evaluation</span> of the cost and profitability of production is key in determining, whether this project should be carried on after iGEM. These estimates shows if our presumption of the competitiveness are wrong rather than right. The analysis is used to approximate the pricing of the product, since it does not exist on the market as of yet. The aim is to reduce prices by half in comparison to the price of monoclonal antibodies (mAbs), which leaves an acceptable margin between reality and estimates.
+
<span class="intro">A cost analysis</span> is key in estimating profitability, and determining if this project should be carried on after iGEM. These estimates shows if our presumption of the competitiveness are wrong rather than right. The analysis is used to approximate the pricing of the product, since it does not exist on the market as of yet. The aim is to reduce prices by half in comparison to the price of mAbs, which leaves an acceptable margin between reality and estimates.
 
</p>
 
</p>
  
Line 151: Line 151:
 
</span>  
 
</span>  
  
The size of the factory has to be estimated before costs can be calculated, therefore it is necessary to  
+
The size of the factory has to be estimated before costs can be calculated, and therefore it is necessary to  
  
 
evaluate the number of units needed. As established under <a target="_blank" href="https://2015.igem.org/Team:SDU-Denmark/Tour34">entrepreneurship</a> it has been decided to  
 
evaluate the number of units needed. As established under <a target="_blank" href="https://2015.igem.org/Team:SDU-Denmark/Tour34">entrepreneurship</a> it has been decided to  
  
produce several small batches, and the market analysis estimated the amount of batches to be 250 year. According to the timeline a batch cycle is 63.5 [h], and the next batch can begin after a flash  
+
produce several small batches, and the market analysis estimated the amount of batches to be 250 per year. According to the timeline a batch cycle is 63.5 [h], and the next batch can begin after a flash  
  
sterilization of the fermenter, after 42.5 [h] from the start of the batch. This implies, that the cycle time for
+
sterilization of the fermenter, 42.5 [h] from the start of the batch. This implies, that the cycle time of
  
 
two batches is 106 [h]. It is assumed that the plant is closed for 4 [weeks/yr] and a work week consists of 5  
 
two batches is 106 [h]. It is assumed that the plant is closed for 4 [weeks/yr] and a work week consists of 5  
Line 269: Line 269:
 
<p>
 
<p>
 
This calculation shows that an investment of 24.9 [million USD] is needed to get the plant up and running.  
 
This calculation shows that an investment of 24.9 [million USD] is needed to get the plant up and running.  
From this amount 14.4 [million USD] is depreciable.
 
 
</p>
 
</p>
  
Line 279: Line 278:
 
   <div class="pane" style="height:auto;" >
 
   <div class="pane" style="height:auto;" >
 
   <p>
 
   <p>
Now it needs to be approximated how much it will cost PAST to run production annually, this is achieved by
+
An approximation on the annual production cost needs to be estimated, this is achieved by
  
usage of a model, Busche (1995) with modificatio<span class="sourceReference">ns</span>.  
+
usage of the Busche model (1995) with modificatio<span class="sourceReference">ns</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 289: Line 288:
  
  
<table class="wikitable"><caption><b>Table 2: </b></caption>
+
<table class="wikitable"><caption><b>Table 3: </b></caption>
 
<thead>
 
<thead>
 
<tr> <td></td><td>Result [million USD/yr]</td> <td>Source:</td></tr></thead>
 
<tr> <td></td><td>Result [million USD/yr]</td> <td>Source:</td></tr></thead>
Line 356: Line 355:
 
</span> &nbsp; Chapter 23.2</td></tr>
 
</span> &nbsp; Chapter 23.2</td></tr>
  
<tr><td><b>Total labor-related Operations (O)</b> </td><td><b>1.4 </b></td><td><span class="sourceReference">  </span>  
+
<tr><td><b>Total labor-related Operations</b> </td><td><b>1.4 </b></td><td><span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 391: Line 390:
 
</span> &nbsp; Chapter 23.2</td></tr>
 
</span> &nbsp; Chapter 23.2</td></tr>
  
<tr><td><b>Total Maintenance (M)</b></td><td><b>1.5</b></td><td><span class="sourceReference">  </span>  
+
<tr><td><b>Total Maintenance</b></td><td><b>1.5</b></td><td><span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 433: Line 432:
 
</span> &nbsp; Chapter 23.2</td></tr>
 
</span> &nbsp; Chapter 23.2</td></tr>
  
<tr><td><b>Property taxes and insurance (t) </b></td><td><b>0.3 </b></td><td><span class="sourceReference">  </span>  
+
<tr><td><b>Property taxes and insurance </b></td><td><b>0.3 </b></td><td><span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 454: Line 453:
 
</span> &nbsp; Chapter 23.2</td></tr>
 
</span> &nbsp; Chapter 23.2</td></tr>
  
<tr><td><b>Total depreciation (D) </b></td><td><b>1.08 </b></td><td><span class="sourceReference">  </span>  
+
<tr><td><b>Total depreciation </b></td><td><b>1.08 </b></td><td><span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 461: Line 460:
 
</span>&nbsp; Chapter 23.2</td></tr>
 
</span>&nbsp; Chapter 23.2</td></tr>
  
<tr><td><b>Total cost of manufacturing (COM)</b> </td><td><b>8.6 </b></td><td><span class="sourceReference">  </span>  
+
<tr><td><b>Total cost of manufacturing</b> </td><td><b>8.6 </b></td><td><span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 468: Line 467:
 
</span> &nbsp;Chapter 23.2</td></tr>
 
</span> &nbsp;Chapter 23.2</td></tr>
  
<tr><td><b>Total general expenses (GE) </b></td><td><b>0.2 </b></td><td><span class="sourceReference">  </span>  
+
<tr><td><b>Total general expenses </b></td><td><b>0.2 </b></td><td><span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 474: Line 473:
 
<a target="_blank" href="http://www.rand.org/content/dam/rand/pubs/monograph_reports/MR1325/MR1325.ch9.pdf "> (accessed: 15.09.2015)
 
<a target="_blank" href="http://www.rand.org/content/dam/rand/pubs/monograph_reports/MR1325/MR1325.ch9.pdf "> (accessed: 15.09.2015)
 
</span> &nbsp;  Rand Corporation</td></tr>
 
</span> &nbsp;  Rand Corporation</td></tr>
<tr><td><b>Total cost of production (C) </b></td><td><b>8.8 </b></td><td><span class="sourceReference">  </span>  
+
<tr><td><b>Total cost of production </b></td><td><b>8.8 </b></td><td><span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 488: Line 487:
 
   </p>
 
   </p>
 
<p>
 
<p>
This concludes that according to this model, it will cost 8.8 [million USD/yr] for PAST to produce 250  
+
This concludes that according to the model, it will cost 8.8 [million USD/yr] for PAST to produce 250  
  
 
batches.
 
batches.
 
</p>
 
</p>
 
   </div>
 
   </div>
<div class="accordionTitel"> Pricing and Profibility </div>
+
<div class="accordionTitel"> Pricing and Profitability </div>
 
   <div class="pane" style="height:auto;" >
 
   <div class="pane" style="height:auto;" >
 
   <p>
 
   <p>
 
The challenge of biotech companies is to price a product that is of yet not on the market. This has to be an  
 
The challenge of biotech companies is to price a product that is of yet not on the market. This has to be an  
  
evaluation of the costs estimated above and the investments needed for maturing the concept on the one  
+
evaluation of the costs estimated above and the investments needed for maturing the concept on one  
  
hand. On another how much customers are willing to pay. PAST aims to replace mAbs, and it must be  
+
hand, and how much customers are willing to pay on the other. PAST aims to replace mAbs, and it must be  
  
 
assumed that though there are concerns of animal welfare, the customers will be inclined to keep using  
 
assumed that though there are concerns of animal welfare, the customers will be inclined to keep using  
  
mAbs, if the price of the peptide aptamers are not considerably lower. Therefore an average of the price  
+
mAbs, if the price of the peptide aptamers are not considerably lower. Therefore an average of the price of
  
mAbs has been estimated by 50 products from Sigma-Aldrich, details can be viewed in pdf (<a target="_blank" href="https://static.igem.org/mediawiki/2015/0/01/SDU2015_sigma-aldrich_antibodies.pdf">Sigma-Aldrich antibodies</a>). Showing an  
+
mAbs has been estimated by 50 products from Sigma-Aldrich, details can be viewed in the following pdf (<a target="_blank" href="https://static.igem.org/mediawiki/2015/0/01/SDU2015_sigma-aldrich_antibodies.pdf">Sigma-Aldrich antibodies</a>). Assessment of the pricing shows an average price of 1.7 [million USD/g]. This method of pricing presupposed that the peptide aptamers have
  
average price of 1.7 [million USD/g]. This method of pricing presupposed that the peptide aptamers have
+
the same affinity and specificity as mAbs. The definition of sales can be viewed in equation 1, and it should be
  
the same affinity and specificity as mAbs. The definition of sales can be viewed in equation 1, it should be
+
noted that it is assumed that 30 % of production is lo<span class="sourceReference">st</span>.  
 
+
noted, that it is assumed that 30 % of production is lo<span class="sourceReference">st</span>.  
+
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 522: Line 519:
  
 
<p>
 
<p>
In the figure the development of sales and net earnings in relation to a price of 1-100% of that of mAbs can  
+
In figure 5 net earnings can be viewed. Net earnings has been calculated from equation <span class="sourceReference">2</span>.  
 
+
be viewed. Net earnings has been calculated from equation <span class="sourceReference">2</span>.  
+
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 532: Line 527:
 
</p>  
 
</p>  
 
<p style="margin-left:310px;"> Net earnings = (1 - t)(S - C) (2)</p>
 
<p style="margin-left:310px;"> Net earnings = (1 - t)(S - C) (2)</p>
 +
<p style="margin-left:310px;">where C=Cost of production</p>
 +
<p style="margin-left:310px;">and t=Property taxes and insurance</p>
  
  
 
<p>
 
<p>
This confirms the assumption, that this production method can render profit at a price lower than that of mAbs. Though it does not take into account the investments in the plant. Therefore three different methods are used for estimating the profitability, see table. These methods cannot be compared directly, but if all shows profitability, it must be assumed, that grounds to work further with the idea is establish<span class="sourceReference">ed</span>.  
+
The goal of PAST is to sell the product at least 50% cheaper than of mAbs. Figure 5 shows that PAST will render positive net earnings and achieve this goal at prices in the range of 1.5-50% of mAbs.These calculations does not take into account the investments in the plant. Therefore three different methods were used for estimating the profitability, see table 3. They cannot be compared directly, but if all shows profitability, it must be assumed, that grounds to work further with the idea is establish<span class="sourceReference">ed</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 544: Line 541:
  
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:255px; height:260px;">
+
<div class="thumbinner" style="width:255px; height:230px;">
 
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/2/29/SDU2015_Development_of_sales.png" title="">
 
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/2/29/SDU2015_Development_of_sales.png" title="">
   <img src="https://static.igem.org/mediawiki/2015/2/29/SDU2015_Development_of_sales.png" style="width:250px"/>
+
   <img src="https://static.igem.org/mediawiki/2015/9/9e/SDU2015_Development_of_sales_thumbnail.png" style="width:250px"/>
 
     </a>
 
     </a>
     <div class="thumbcaption"><i> Figure 4:</i> Development of sales and net earnings </div>
+
     <div class="thumbcaption">Figure 6: Net earnings compared to the price of mAbs, it is noted that within the range of 1.5-50% of the price of mAbs, the net earnings are positive. </div>
 
</div>
 
</div>
 
</div>
 
</div>
Line 565: Line 562:
 
Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010
 
Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010
 
</span>  &nbsp;table 22.5 </td></tr>
 
</span>  &nbsp;table 22.5 </td></tr>
 +
 +
<tr><td> </td><td> C<sub>TCI=Total capital investment </td><td> </td></tr>
 +
 +
 
<tr><td>Payback period   </td>  <td>PBP=C<sub>TDC</sub>/((1-t)(S-C)+D)             </td><td> <span class="sourceReference">  </span>  
 
<tr><td>Payback period   </td>  <td>PBP=C<sub>TDC</sub>/((1-t)(S-C)+D)             </td><td> <span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
Line 571: Line 572:
 
Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010
 
Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010
 
</span> &nbsp;table 22.5</td></tr>
 
</span> &nbsp;table 22.5</td></tr>
 +
 +
<tr><td> </td><td> C<sub>TDC=Total depriciable cost </td><td> </td></tr>
 +
<tr><td> </td><td> D=Depriciation </td><td> </td></tr>
 +
 
<tr><td>Venture profit         </td>  <td>VP=(1-t)(S-C)-i<sub>min</sub> C<sub>TCI</<sub> </td><td> <span class="sourceReference">  </span>  
 
<tr><td>Venture profit         </td>  <td>VP=(1-t)(S-C)-i<sub>min</sub> C<sub>TCI</<sub> </td><td> <span class="sourceReference">  </span>  
 
<span class="tooltip">
 
<span class="tooltip">
Line 583: Line 588:
  
 
<div class="thumb tright">
 
<div class="thumb tright">
<div class="thumbinner" style="width:255px; height:260px;">
+
<div class="thumbinner" style="width:255px; height:220px;">
 
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/5/52/Evaluation_of_profitability_kopi.png" title="">
 
<a class="popupImg alignRight" style="width:250px" target="_blank" href="https://static.igem.org/mediawiki/2015/5/52/Evaluation_of_profitability_kopi.png" title="">
 
   <img src="https://static.igem.org/mediawiki/2015/5/52/Evaluation_of_profitability_kopi.png" style="width:250px"/>
 
   <img src="https://static.igem.org/mediawiki/2015/5/52/Evaluation_of_profitability_kopi.png" style="width:250px"/>
 
     </a>
 
     </a>
     <div class="thumbcaption"><i> Figure 5:</i> Evaluation of profitability  </div>
+
     <div class="thumbcaption">Figure 7: Evaluation of profitability  </div>
 
</div>
 
</div>
 
</div>
 
</div>
  
 
<p>
 
<p>
The goal is to sell the peptide aptamers at least at 50% of the price of mAbs, therefore the methods are used for a price range between 1-50 %. Parameters for profitability of the three methods are: ROI>0 %, PBP<2 [yr]  and VP>0 [million/yr]. Results can viewed in figu<span class="sourceReference">re</span>.  
+
The goal is to sell the peptide aptamers at least at 50 % of the price of mAbs, therefore the methods are used for a price range between 1-50 %. Parameters for profitability of the three methods are: ROI>0 %, PBP<2 [yr]  and VP>0 [million/yr]. Results can viewed in figu<span class="sourceReference">re</span>.  
 
<span class="tooltip">
 
<span class="tooltip">
 
   <span class="tooltipHeader">Reference:</span>
 
   <span class="tooltipHeader">Reference:</span>
Line 604: Line 609:
  
 
<p>
 
<p>
The evaluation shows, that PAST will be profitable at a price above 4 % that of mAbs, which corresponds to a price of 0.07 [million USD/g]. It is most unlikely that investors can be paid back at this price, and should be taken as an indication of the margin in pricing. In this estimate it will be possible to raise prices by 44% before exceeding the goal. Another uncertainty is the validity of the estimate, since this is only an approximation of reality. Therefore the same calculations were done, if the cost turns out to be double. This showed profitability at a price set at 8% that of mAbs, which corresponds to a price of 0.13 [million USD/g].  
+
The evaluation shows, that PAST will be profitable at a price above 4 % that of mAbs, which corresponds to a price of 0.07 [million USD/g]. It is most unlikely that investors can be paid back at this price, and should be taken as an indication of the margin in pricing. In this estimate it will be possible to raise prices by 44 % before exceeding the goal. Another uncertainty is the validity of the estimate, since this is only an approximation of reality. Therefore the same calculations were done, if the cost turns out to be double. This showed profitability at a price set at 8 % that of mAbs, which corresponds to a price of 0.13 [million USD/g].  
 
This leads to the conclusion, that there is a good possibility of making a profitable enterprise, and it should be encourage to keep working towards more accurate estimates and finally the realization of PAST.  
 
This leads to the conclusion, that there is a good possibility of making a profitable enterprise, and it should be encourage to keep working towards more accurate estimates and finally the realization of PAST.  
 
<br>
 
<br>
 
<br>
 
<br>
 
<br>
 
<br>
<br>
+
 
<br>
+
<br>
+
<br>
+
<br>
+
 
</p>
 
</p>
 
   </div>
 
   </div>

Latest revision as of 16:15, 4 October 2015

"Alberto is an expert in the disposal business." - Alejandro Sosa: Scarface

Business

Figure 1: Business model canvas for PAST.

We in PAST believe that our product is a valuable addition to the toolbox of researchers and educators. But believing is not knowing, and therefore an investigation was conducted to conclude whether this presumption is wrong. This evaluation consists of a business canvas, a market analysis based on iGEM teams from 2014 and a cost analysis, allowing us to assess if profit margins are large enough to verify our assumption.

A market analysis was conducted to determine how many batches PAST should be able to produce per year. The analysis is based on the competitors of iGEM 2014. These teams are at the forefront of synthetic biology and therefore it is assumed, that they represent the future of the field. Every team who has succeeded in making their wiki has been considered. The results can be viewed in the following pdf (Market analysis iGEM 2014).

Team distribution
Figure 2: Chart of the global distribution of teams

The market is presumed to be worldwide. The distribution of teams, which can be viewed in figure 2, shows an even distribution in all but one region. This underrepresentation by Latin America can be caused by several factors, but for now it is considered a future market, and no correlations will be made.








Teams using antibodies
Figure 3: Chart of teams using antibodies distributed in regions

We have investigated how many teams according to regions that have used antibodies in their project. The results are depicted in figure 3. Though Europe only represents 28 % of the total teams, these teams use 55% of the totale usage of antibodies, whereas North American teams used antibodies half as much as they are represented. Several reasons can be responsible for this under- and overrepresentation. If it is assumed, that all teams producing proteins could potentially use antibodies, it is a possibility that projects on this subject is more common in Europe than in North America. This will be investigated next.







Teams producing proteins
Figure 4: Chart of teams producing protein in regards to regions

Figure 4 shows that the teams producing proteins follow the general distribution globally, therefore there is no correlation between protein production and the uneven distribution of antibody usage. It has not been possible to determine if resources is the cause of the bias, but this does not seem unreasonable. If that is the case, teams will benefit from PAST’s product globally.

Teams producing proteins and teams using antibodies has been compared in figure 4. This shows that only a few actually use antibodies. This could be due to teams not reaching a point, where assays using antibodies are necessary, rather than a lack of resources. However, it has been decided to ignore this as a reason, since it must be assumed, that research projects generally have more time to evolve. Therefore it has been decided to base the estimate of production size on the protein production rather than antibody usage.

Figure 5:comparison of protein production and antibody usage

Using the assumption an estimate can be made. A total of 123 teams where involved in projects producing proteins, and on average the teams used two types of antibodies per project. Therefore a production of approximately 250 varieties of peptide aptamers is presumed appropriate. Though this estimates the number of batches per year, each project will only buy a small amount of the production. Therefore it should be evaluated if, it is reasonable to assume that the rest of the production can be sold as well. To reach a conservative estimate the European market has been evaluated, as this is the region where most antibodies where used. 63 universities were represented at iGEM 2014 out of approximately 4000 academic institutions in Europe. Reference: European Union. The role of universities in the Europe of knowledge. (Link) (Accessed August 21st 2015). Taking these numbers into consideration, iGEM 2014 represents 1.6 % of the market. Assuming only one research project per university is using antibodies, which is unlikely, this evaluation reinforces the assumption, that the remaining product can be sold. In some instances this will not be the case, due to the specialized nature of production or property rights. Therefore it is estimated that 30 % of the production will be lost.

A cost analysis is key in estimating profitability, and determining if this project should be carried on after iGEM. These estimates shows if our presumption of the competitiveness are wrong rather than right. The analysis is used to approximate the pricing of the product, since it does not exist on the market as of yet. The aim is to reduce prices by half in comparison to the price of mAbs, which leaves an acceptable margin between reality and estimates.

Capital Investment

To estimate how much capital is needed to build the plant, the Busche model (1995) with modifications has been used. Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010 The size of the factory has to be estimated before costs can be calculated, and therefore it is necessary to evaluate the number of units needed. As established under entrepreneurship it has been decided to produce several small batches, and the market analysis estimated the amount of batches to be 250 per year. According to the timeline a batch cycle is 63.5 [h], and the next batch can begin after a flash sterilization of the fermenter, 42.5 [h] from the start of the batch. This implies, that the cycle time of two batches is 106 [h]. It is assumed that the plant is closed for 4 [weeks/yr] and a work week consists of 5 days (120 [h]). Which means that 3 set-ups are needed. This assumption leaves a time buffer in case of unforeseen maintenance or orders.

Table 1: Estimate of the total capital investment
Result
[million USD]
Source:

Total bare-module investment


7.6


Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Simulation Aspen Plus, method BK10
Reference: E-mail from GE lifescienses   linear extrapolation of price development
Cost of site preparation 1.1 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Cost of service facilities 0.6 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Allocated costs for utility plants and related facilities

2.9

Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3; table 22.12
Simulation Aspen Plus, method BK10
Total direct permanent investment 12.2 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Cost of contingencies and contractor’s fee 2.2 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Total depreciable capital 14.4 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Cost of land 0.3 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Cost of plant startup 3.6 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Total permanent investment 21.6 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010  chapter 22.3
Working capital 3.2 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3
Total captital investment 24.9 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   chapter 22.3

Note: several minor cost calculations such as that of pumps has been ignored.

This calculation shows that an investment of 24.9 [million USD] is needed to get the plant up and running.

Cost of Production

An approximation on the annual production cost needs to be estimated, this is achieved by usage of the Busche model (1995) with modifications. Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010


Table 3:
Result [million USD/yr] Source:
Total Feedstock



3.5



Entrepreneurship
Reference: Available from: [Sigma-Aldrich] (accessed: 10.09.2015)   Sigma-Aldrich
Reference: Available at:
[NEB] (accessed: 13.09.2015)   NEB
Electricity 0.3 Simulation Aspen Plus, methods BK10 and Water
Cooling water 0.00004 Simulation Aspen Plus, methods BK10 and Water
Process water 0.003 Entrepreneurship
Total utilities 0.32 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Direct wages and benefits 1.09 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Equation 23.2 and table 23.3
Direct salaries and benefits 0.16 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Operating supplies and services 0.07 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Technical assistance to manufacturing 0.02 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Control laboratory 0.02 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Total labor-related Operations 1.4 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Wages and benefits 0.6 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Salaries and benefits 0.2 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Materials and services 0.6 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Maintenance overhead 0.03 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Total Maintenance1.5 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
General plant overhead 0.1 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Mechanical department services 0.05 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Employee relations department 0.1 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Business services 0.2 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Total operation overhead 0.47 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Property taxes and insurance 0.3 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Direct plant 0.88 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Allocated plant 0.21 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Total depreciation 1.08 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2
Total cost of manufacturing 8.6 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010  Chapter 23.2
Total general expenses 0.2 Reference: Available at: (accessed: 15.09.2015)   Rand Corporation
Total cost of production 8.8 Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010   Chapter 23.2

This concludes that according to the model, it will cost 8.8 [million USD/yr] for PAST to produce 250 batches.

Pricing and Profitability

The challenge of biotech companies is to price a product that is of yet not on the market. This has to be an evaluation of the costs estimated above and the investments needed for maturing the concept on one hand, and how much customers are willing to pay on the other. PAST aims to replace mAbs, and it must be assumed that though there are concerns of animal welfare, the customers will be inclined to keep using mAbs, if the price of the peptide aptamers are not considerably lower. Therefore an average of the price of mAbs has been estimated by 50 products from Sigma-Aldrich, details can be viewed in the following pdf (Sigma-Aldrich antibodies). Assessment of the pricing shows an average price of 1.7 [million USD/g]. This method of pricing presupposed that the peptide aptamers have the same affinity and specificity as mAbs. The definition of sales can be viewed in equation 1, and it should be noted that it is assumed that 30 % of production is lost. Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010

S=Price x 0.70Production (1)

In figure 5 net earnings can be viewed. Net earnings has been calculated from equation 2. Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010

Net earnings = (1 - t)(S - C) (2)

where C=Cost of production

and t=Property taxes and insurance

The goal of PAST is to sell the product at least 50% cheaper than of mAbs. Figure 5 shows that PAST will render positive net earnings and achieve this goal at prices in the range of 1.5-50% of mAbs.These calculations does not take into account the investments in the plant. Therefore three different methods were used for estimating the profitability, see table 3. They cannot be compared directly, but if all shows profitability, it must be assumed, that grounds to work further with the idea is established. Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010

Figure 6: Net earnings compared to the price of mAbs, it is noted that within the range of 1.5-50% of the price of mAbs, the net earnings are positive.

Table 3: methods of evaluating profitability
Method Equation Source
Return of investment ROI=(1-t)(S-C)/CTCI Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010  table 22.5
CTCI=Total capital investment
Payback period PBP=CTDC/((1-t)(S-C)+D) Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010  table 22.5
CTDC=Total depriciable cost
D=Depriciation
Venture profit VP=(1-t)(S-C)-imin CTCI Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010  table 22.5

Figure 7: Evaluation of profitability

The goal is to sell the peptide aptamers at least at 50 % of the price of mAbs, therefore the methods are used for a price range between 1-50 %. Parameters for profitability of the three methods are: ROI>0 %, PBP<2 [yr] and VP>0 [million/yr]. Results can viewed in figure. Reference: Seider, Seader, Lewin and Widagoo. Product and Process Design Principles - Synthesis, Analysis, and Evaluation; Third Edition - International Student Version; John Wiley & Sons, Inc.; 2010

The evaluation shows, that PAST will be profitable at a price above 4 % that of mAbs, which corresponds to a price of 0.07 [million USD/g]. It is most unlikely that investors can be paid back at this price, and should be taken as an indication of the margin in pricing. In this estimate it will be possible to raise prices by 44 % before exceeding the goal. Another uncertainty is the validity of the estimate, since this is only an approximation of reality. Therefore the same calculations were done, if the cost turns out to be double. This showed profitability at a price set at 8 % that of mAbs, which corresponds to a price of 0.13 [million USD/g]. This leads to the conclusion, that there is a good possibility of making a profitable enterprise, and it should be encourage to keep working towards more accurate estimates and finally the realization of PAST.